Prurigo Nodularis



In 1909, Hyde and Montgomery[1] first described prurigo nodularis as pruritic nodules on the extensor surfaces of the lower extremities in middle-aged women. Prurigo nodularis can be a bothersome-to-debilitating disease, usually seen as multiple, intensely pruritic, excoriated nodules erupting on the extensor surfaces of the limbs secondary to itching or rubbing. In current practice, prurigo nodularis is still a condition of unknown etiology. Many conditions have been reported to induce prurigo nodularis, from internal malignancy to renal failure to psychiatric conditions.


Chronic mechanical trauma to the skin causes thickening of the skin proportionate to the trauma. Repetitive rubbing, scratching, and touching (induced by a foreign body or self-induced) results in plaques or nodular lichenification and hyperkeratosis. Pigmentary changes often result from such repetitive trauma to the skin.

With prurigo nodularis, a person feels intense pruritus at discrete points and cannot control the urge to rub or scratch these points on the body. Any abnormality or explanation for the pruritus is unknown; scratching by the individuals who are affected is obvious. The results are discrete, nodular, hyperpigmented/purpuric lesions with surfaces that are scaly, excoriated, and possibly crusted.

Immunohistochemical studies demonstrate increased numbers of dermal nerve fibers in prurigo nodularis. The sensation of pruritus is transmitted mainly by thin, unmyelinated epidermal nerves. Lesional and uninvolved prurigo nodularis skin biopsies showed significantly decreased intraepidermal nerve fiber density, suggesting the presence of a subclinical small fiber neuropathy in prurigo nodularis.[2] However, in a 2017 study, it was suggested that scratching may be the cause of the reduced intradermal nerve fiber density and not an underlying neuropathy.[3] It was demonstrated that lesions that had healed had a full reconstitution of intradermal nerve fiber density, which supports the theory that the disturbed epidermal anatomy is secondary to the mechanical trauma rather than a functional neuropathy.[3] Another study indicated that Th2 cytokines related to STAT6 activation together with some unknown stimuli that activate STAT3 play a principal role in the pathogenesis of prurigo nodularis.[4]



No racial disparity is known for prurigo nodularis.


Women were formerly believed to have a disproportionate amount of prurigo nodularis compared to men; however, no documented difference exists in frequency between the sexes.


Prurigo nodularis can occur at any age, but it most often occurs in middle-aged and older persons.


Prurigo nodularis is benign and does not increase mortality; however, severe morbidity can occur in untreated and even in some treated persons who are affected. Pruritus and the extent of body surface area involved become so great for some patients that they no longer feel functional for work or other everyday activities.

Some conditions associated with prurigo nodularis may cause mortality. Prurigo nodularis has been documented to be much more common in immunocompromised and HIV populations. The positive predictive value (PPV) for HIV positivity was 36% for prurigo nodularis in a study from French Guiana. The PPV for having a CD4 lymphocyte count of less than 200/mcL was 72% for prurigo nodularis. Prurigo nodularis was thus predictive of advanced immunosuppression, and, in the absence of facilities to perform a CD4 count, this study suggests that HIV antiretrovirals should be initiated for patients with prurigo nodularis in third world countries.[5]

Some cases of prurigo nodularis are associated with internal malignancy. Hodgkin disease (lymphoma) may present with pruritus and lichenified nodules.[6] Prurigo nodularis may be the first manifestation of chronic autoimmune cholestatic hepatitis[7] and may be seen with severely decreased kidney function and uremic pruritus.

The prognosis for spontaneous remission of prurigo nodularis is not good. Once prurigo nodularis lesions occur, complete resolution of lesions is uncommon. Most lesions remain present in some form even after long-term treatment. At this time, treating more than just the most symptomatic lesions is difficult. Considerable time is usually required to slow or stop the itch/scratch cycle so that the lesions resolve.

Ultimately, a strong therapeutic alliance is the best outcome predictor because the course of the disease is long, with waxing and waning symptoms, making the patient prone to being subjected to excessive diagnostic procedures and to seek alternative therapies.


Prurigo nodularis patients are most often middle-aged to elderly. Patients with prurigo nodularis invariably complain of a long-standing history of severe, unremitting pruritus. Patients can point out specific sites where they began feeling itchy and where dark-colored nodules form soon after. Mature nodules rarely increase or decrease in size; spontaneous resolution is even more rare. Prurigo nodularis is usually bilaterally symmetric, with nodules that are either stable or increasing in number.

Prurigo nodularis may be a spectrum with a recent classification of the variant umbilicated prurigo. Umbilicated prurigo has identical clinical and microscopic features of acquired reactive perforating dermatosis and classical components of prurigo nodularis. Umbilicated prurigo meets all the histologic criteria for prurigo nodularis, which increases the consideration of it being a subtype of prurigo nodularis. Umbilicated prurigo is assumed to develop preferentially in the context of metabolic disease, such as diabetes mellitus or uremia, owing to these patients’ reduced wound healing capacities.[8]

The patient's medical history may be significant for several conditions, as follows:

Patients may have no significant medical or psychiatric history. The patient's history often reveals a long list of over-the-counter and/or prescribed medications (topical and oral), which usually have produced little or no relief of symptoms. Up to 80% of patients have a personal or family history of atopic dermatitis, asthma, or hay fever (compared with approximately 25% of the normal population).

Physical Examination

Prurigo nodularis nodules or papules are 3-20 mm in diameter; they are discrete, scaly, generally symmetric, hyperpigmented or purpuric, and firm. Nodules and papules occur on the extensor surfaces of the arms, the legs, and sometimes the trunk.

Prurigo nodularis lesions may show signs of excoriation with flat, umbilicated, or crusted top. Lesions may number from 1-2 to hundreds. The nodule pattern may be follicular. Upon entering the examination room and while patients' describe the locations of the lesions, patients may scratch or rub the lesions rather than pointing to them. Many prurigo nodularis patients appear very anxious, worried, or even obsessed with the nodules. Note the images below.

View Image

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.

View Image

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.


The cause of prurigo nodularis is still unknown. Many associated conditions are known, but their roles as coexisting or preexisting conditions have not been established in causing prurigo nodularis. Notable changes in papules and nodules are increased in certain inflammatory cell types, inflammatory products, and neural hyperplasia.

Mast cells and neutrophils are seen in higher-than-normal levels in prurigo nodularis; however, their degranulation products are not increased. Eosinophils are not seen in higher numbers; however, the protein granule products (ie, major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin) are seen in significantly higher levels.

Papillary dermal nerves and Merkel cells are sensory nerves found in the dermis and the epidermis, respectively.[11] They are both found in increased numbers in prurigo nodularis. These are neural receptors that sense touch, temperature, pain, and itch. These increases in sensory nerves are not seen in lichen simplex chronicus, another pruritic disease that causes epidermal hyperplasia but in a plaquelike morphology.

Calcitonin gene–related peptide and substance P immunoreactive nerves are markedly increased in prurigo nodularis skin compared with normal skin.[12] These neuropeptides may mediate the cutaneous neurogenic inflammation and pruritus in prurigo nodularis. In addition, the capsaicin-binding nonselective cation channel known as vanilloid receptor subtype 1 has highly increased expression in epidermal keratinocytes and nerve fibers in prurigo nodularis lesions, but these can be normalized with capsaicin application.

Hepatitis C, mycobacteria,[13, 14, 15] Helicobacter pylori, Strongyloides stercoralis,[16] and HIV have been reported as infectious etiologies of prurigo nodularis or as associated with prurigo nodularis in case reports or from single-center studies.

Interleukin 31, a T-cell–derived cytokine that causes severe pruritus and dermatitis in transgenic mice, is elevated in individuals with prurigo nodularis.[17] Interleukin 31 expression in atopic individuals is also rapidly induced by staphylococcal superantigen; however, the link between these findings has not been extensively researched.


Some healed lesions show pigmentary changes and scarring.

Laboratory Studies

Perform a CBC count and a chemistry panel, including liver function tests (LFTs), to help exclude underlying hematologic malignancies, renal failure, and hepatic diseases.


Obtaining skin biopsy samples of prurigo nodularis lesions for histologic examination and/or cultures may be indicated to exclude squamous cell carcinoma (particularly the keratoacanthoma type) and infections (especially deep fungal, atypical mycobacterial).

Patch testing to exclude contact sensitivity may be considered, particularly with coexisting dermatitis.

Histologic Findings

The histologic features of prurigo nodularis[20] include a hyperkeratotic epidermis with acanthosis and parakeratosis. Rete ridges are elongated and irregular with a dense dermal infiltrate consisting of neutrophils, eosinophils, histiocytes, and monocytes.[21] Also notable in the dermis are thickened nerve fibers and fibrosis with thickened collagen bundles. Thickened nerve fibers are dilated on electron microscopy. Schwann cells show vacuolization and degeneration with no detectable mitochondria. Axons and Schwann cells both show hyperproliferation.[20, 22]

Highly characteristic for prurigo nodularis is the presence of thick, compact orthohyperkeratosis; irregular epidermal hyperplasia or pseudoepitheliomatous hyperplasia; focal parakeratosis or superficial epithelial necrosis; hypergranulosis; fibrosis of the papillary dermis with vertically arranged collagen fibers; increased number of fibroblasts and capillaries; a superficial, perivascular and/or interstitial inflammatory infiltrate of lymphocytes, macrophages and, to a lesser extent, eosinophils and neutrophils. Correlation of clinical and histological findings is necessary to reliably distinguish between prurigo nodularis and lichen simplex chronicus,[23] although both disorders may coexist in the same patient and both are a reaction to rubbing or scratching the skin.

Medical Care

Current available treatments of prurigo nodularis have had mild-to-moderate success at best. Often, combinations of several medications or physical modalities may be used in an attempt to control this process.

Topical, oral, and intralesional corticosteroids have all been used in prurigo nodularis in attempts to decrease inflammation and sense of itching and to soften and smooth out firm nodules. The improvement with corticosteroids is variable, and corticosteroids are sometimes not helpful. The response may be improved with the use of occlusive dressings or soak-and-smear therapy. Intralesional corticosteroid (usually triamcinolone acetonide) treatment is commonly used in resistant cases of limited extent. Triamcinolone acetonide concentrations as low as 2.5 mg/mL may be effective, although more scarred pruriginous lesions may require higher concentrations. A total dose of 20 mg (8 mL of 2.5 mg/mL) for adults every 3-4 weeks is safe for patients without diabetes mellitus or hypertension. An 8-am serum cortisol test can be performed if concerns exist about adrenal suppression.[24]

Menthol, phenol, pramoxine, capsaicin cream,[25, 26] vitamin D-3 ointment,[27] and topical anesthetics are some other topical agents used to reduce pruritus. Treatment with DuoDerm or other occlusive therapies has been suggested to flatten lesions while at the same time preventing patients from directly scratching nodules.[28]

Phototherapy treatment has limited studies showing potential benefits and efficacy but psoralen plus ultraviolet (UV)–A (PUVA), broadband UV-B, narrowband UV-B, excimer laser, and UV-A have been used with success, with no evidence that any modality is superior to the other.[29] Consider the adverse effects of prolonged UV exposure before such treatment. Monochromatic 308-nm light therapy may be helpful for recalcitrant lesions,[30] although this modality may be more useful in atopic dermatitis.[31] The combination of UV-B 308-nm excimer light and bath PUVA therapy may be effective in the treatment of prurigo nodularis. Resistant nodules have been successfully treated with excimer lasers as well.[32, 29] UV-A1 has also been reported to benefit lichen simplex chronicus and prurigo nodularis.[33]

Antihistamines, anxiolytics, opiate receptor antagonists, and thalidomide are oral medications other than steroids used for prurigo nodularis. Thalidomide[34, 35, 36] has been shown to aid in several severe dermatoses, including prurigo nodularis with or without associated HIV disease.[37, 38, 39] Severe teratogenic effects are well known and documented, and all women of childbearing age should be on adequate birth control methods. Patients taking thalidomide have an increased risk of peripheral neuropathy and sedation is common. Approximately 20% of patients on thalidomide develop peripheral neuropathy within the first year on the medication.[40] Options to reduce and avoid potential adverse effects of thalidomide are to treat with a sequential combination of thalidomide with UV-B therapy or thalidomide followed by its analogue lenalidomide to shorten the treatment length for thalidomide.[10] Lenalidomide is 2000 times more potent than thalidomide.[40] Lenalidomide as a single treatment can be an option for patients with prurigo nodularis that is recalcitrant to thalidomide and other therapies. Lenalidomide is also not without its risk, as it can cause myelosuppression more frequently than thalidomide and has an increased risk for thromboembolic events. The benefit of lenalidomide is that peripheral neuropathy is less frequent and the risk for thromboembolic events can be mitigated by taking aspirin with lenalidomide.[40] Studies on thalidomide and lenalidomide are all small case studies with low power, but treatment with these medications has yielded positive results with moderate-to-significant improvement in the majority of the cases.[10]

For steroid-unresponsive patients or those with lesions on thin skin, a few case reports and small studies have shown efficacy of the topical immunomodulators tacrolimus and pimecrolimus. Multiple small case studies showed potential for the use of methotrexate, a folic acid antagonist widely used for autoimmune inflammatory disorders such as psoriasis.[41, 42] Low-dose parenteral methotrexate reduced the pruriginous nature of the lesions and has shown potential for long-term remission.[41, 42]

Anecdotally, gabapentin has been reported to benefit lichen simplex chronicus and prurigo nodularis for some cases.[43, 44] Sedation is the main problem with this generic medication.

Habit reversal therapy for the itch-scratch cycle associated with prurigo nodularis may be helpful and can be administered by dermatology nurses trained in this therapy.[45]

Substance P (SP) is a major mediator of pruritus. It binds to the neurokinin receptor 1 (NKR1). The NKR1 antagonist aprepitant is marketed for prevention of chemotherapy-induced nausea and vomiting and for prevention of postoperative nausea and vomiting and may benefit patients with prurigo nodularis.[46]

Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus. Kappa-opioid receptors agonists bind to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. Nalfurafine, a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan.[47]

Surgical Care

Cryotherapy with liquid nitrogen helps reduce pruritus and flatten lesions.[48, 49] This modality can be particularly helpful in upper limb and trunk lesions for patients with diabetes mellitus or in patients with hypertension to minimize adverse effects of intralesional and highly potent topical corticosteroids. Thirty-second thaw cycles with 2-4 treatments are recommended, depending on the size of the lesion. Understanding the risks of scarring and change in pigmentation (especially in darker-skinned individuals) is important. Cryotherapy may be combined with other modalities (eg, intralesional corticosteroids).

Pulsed-dye laser therapy may help reduce the vascularity of individual lesions.


Pay special attention to patients with prurigo nodularis. Take a careful history of immune compromise or other internal disease. Refer patients to an internist or a family physician for possible further investigation and examination. Some patients benefit from psychiatric referral once underlying dermatologic and medical disorders have been excluded.[50]


Instruct prurigo nodularis patients to minimize touching, scratching, and rubbing affected areas.

Long-Term Monitoring

Monitor patients with prurigo nodularis for the following:

Medication Summary

The goal of pharmacotherapy for prurigo nodularis is to break the itch-scratch-itch cycle by reducing pruritus, rubbing, picking, and scratching. One should always consider and rule out treatable endogenous and exogenous causes of pruritus.

Pramoxine topical (Itch-X)

Clinical Context:  Pramoxine topical blocks nerve conduction and impulses by inhibiting depolarization of neurons.

Capsaicin topical (Dolorac, Capsin, Zostrix)

Clinical Context:  Capsaicin topical is derived from plants of the Solanaceae family. It may render skin and joints insensitive to pain by depleting substance P in peripheral sensory neurons.

Class Summary

These agents may control itching by blocking the transmission of nerve impulse.

Calcipotriene (Dovonex)

Clinical Context:  Calcipotriene is a synthetic vitamin D-3 analog used in the treatment of moderate plaque psoriasis.

Class Summary

These agents regulate skin cell production and development.

Methoxsalen (8-MOP, Oxsoralen)

Clinical Context:  Methoxsalen inhibits mitosis by binding covalently to pyrimidine bases in DNA when photoactivated by UV-A.

Class Summary

These agents may be beneficial for patients with severe pruritus.

Diphenhydramine (Benadryl, Belix Oral)

Clinical Context:  Diphenhydramine is first-line treatment for symptomatic relief of pruritus caused by the release of histamine.

Chlorpheniramine (Chlor-Trimeton)

Clinical Context:  Chlorpheniramine is first-line treatment. It competes with histamine or H1 receptor sites on effector cells in blood vessels and the respiratory tract.

Hydroxyzine (Anxanil, Atarax, Atozine, Durrax, Vistaril)

Clinical Context:  Hydroxyzine is a first-line treatment. It antagonizes H1 receptors in the periphery. Hydroxyzine may suppress histamine activity in the subcortical region of the CNS and can be used as an anxiolytic.

Class Summary

These agents may control itching by blocking effects of endogenously released histamine but probably best used as a sedative to control pruritus, especially at night.

Triamcinolone (Kenalog)

Clinical Context:  Triamcinolone is first-line treatment if few lesions (for intralesional use) are present. It is for inflammatory dermatosis responsive to steroids; triamcinolone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.

Intramuscular injection may be used for widespread skin disorders, or intralesional injections may be used for localized skin disorders. Consider limiting the total monthly dose to 20 mg to ensure the HPA axis will not be suppressed.

Clobetasol (Temovate)

Clinical Context:  Clobetasol is first-line treatment (for topical use). It is a class I superpotent topical steroid; it suppresses mitosis and increases the synthesis of proteins that decrease inflammation and cause vasoconstriction. Ointment may be more efficacious than cream secondary to the former's occlusive properties.

Flurandrenolide (Cordran Tape)

Clinical Context:  Flurandrenolide is first-line treatment (for topical use). It also helps protect nodules from continued trauma if tape is left in place.

Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. These agents also modify the body's immune response to diverse stimuli.

Thalidomide (Thalomid)

Clinical Context:  Thalidomide may suppress excessive production of tumor necrosis factor alpha (TNF-alpha) and may down-regulate selected cell-surface adhesion molecules involved in leukocyte migration.

If the patient is less than 50 kg (110 lb), start at the low end of the dose regimen.

Thalidomide can cause severe, life-threatening birth defects and is contraindicated in pregnant women. It is also contraindicated in women of childbearing potential unless using 2 forms of reliable contraception and complying with serial pregnancy testing while on therapy.

Thalidomide is also contraindicated in sexually active men not using latex condom as barrier contraception. The drug is available only under a special restricted distribution program called STEPS (System for Thalidomide Education and Prescribing Safety) Program; only prescribers and pharmacists registered with this program may prescribe and dispense thalidomide. For more information, contact the Celgene Corporation at 1-888-423-5436.

Class Summary

These agents have immunomodulatory effects.

Tacrolimus ointment (Protopic)

Clinical Context:  The mechanism of action of tacrolimus in prurigo nodularis not known. Tacrolimus reduces itching and inflammation by suppressing the release of cytokines from T cells. It also inhibits transcription for genes that encode IL-3, IL-4, IL-5, GM-CSF, and TNF-alpha, all of which are involved in the early stages of T-cell activation. Additionally, it may inhibit the release of preformed mediators from skin mast cells and basophils and down-regulate the expression of FCeRI on Langerhans cells. Tacrolimus can be used in patients as young as 2 years. Drugs of this class are more expensive than topical corticosteroids. Tacrolimus is available as ointment in concentrations of 0.03 and 0.1%. It is indicated only after other treatment options have failed.

Pimecrolimus (Elidel)

Clinical Context:  Pimecrolimus is derived from ascomycin, a natural substance produced by the fungus Streptomyces hygroscopicus var ascomyceticus. It selectively inhibits the production and release of inflammatory cytokines from activated T-cells by binding to the cytosolic immunophilin receptor macrophilin-12. The resulting complex inhibits phosphatase calcineurin, thus blocking T-cell activation and cytokine release. Cutaneous atrophy was not observed in clinical trials, a potential advantage over topical corticosteroids. It is indicated only after other treatment options have failed.

OnabotulinumtoxinA (BOTOX®)

Clinical Context:  OnabotulinumtoxinA is one of several toxins produced by Clostridium botulinum. It blocks neuromuscular transmission through a 3-step process, as follows: (1) blockade of neuromuscular transmission; onabotulinumtoxinA binds to the motor nerve terminal. The binding domain of the type A molecule appears to be the heavy chain, which is selective for cholinergic nerve terminals. (2) OnabotulinumtoxinA is internalized via receptor-mediated endocytosis, a process in which the plasma membrane of the nerve cell invaginates around the toxin-receptor complex, forming a toxin-containing vesicle inside the nerve terminal. After internalization, the light chain of the toxin molecule, which has been demonstrated to contain the transmission-blocking domain, is released into the cytoplasm of the nerve terminal. (3) OnabotulinumtoxinA blocks acetylcholine release by cleaving SNAP-25, a cytoplasmic protein that is located on the cell membrane and that is required for the release of this transmitter. The affected terminals are inhibited from stimulating muscle contraction. The toxin does not affect the synthesis or storage of acetylcholine or the conduction of electrical signals along the nerve fiber. OnabotulinumtoxinA prevents calcium-dependent release of acetylcholine and produces a state of denervation at the neuromuscular junction and postganglionic sympathetic cholinergic nerves in the sweat glands.

Typically, a 24-72 hour delay between administration of toxin and onset of clinical effects exists, which terminate in 2-6 months.

This purified neurotoxin complex is a vacuum-dried form of purified onabotulinumtoxinA , which contains 5 ng of neurotoxin complex protein per 100 U.

OnabotulinumtoxinA has to be reconstituted with 2 mL of 0.9% sodium chloride diluent. With this solution, each 0.1 mL results in 5 U dose. The patient should receive 5-10 injections per visit.

It must be reconstituted from vacuum-dried toxin into 0.9% sterile saline without preservative using manufacturer's instructions to provide injection volume of 0.1 mL; it must be used within 4 hours of storage in the refrigerator at 2-8°C.

Preconstituted dry powder must be stored in a freezer at less than 5°C.

Injections of botulinum toxin must be repeated at varying intervals to maintain long-term results.


Amarateedha H Prak, MD, Naval Flight Surgeon, Marine Corps Air Station Camp Pendleton

Disclosure: Nothing to disclose.


Kristina Marie Dela Rosa, MD, Dermatologist, Insight Dermatology, San Diego, CA

Disclosure: Nothing to disclose.

Specialty Editors

Michael J Wells, MD, FAAD, Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Naked Biome<br/>Received income in an amount equal to or greater than $250 from: Elsevier; WebMD<br/>StatPearls; Editor.

Additional Contributors

Daniel J Hogan, MD, Clinical Professor of Internal Medicine (Dermatology), Nova Southeastern University College of Osteopathic Medicine; Investigator, Hill Top Research, Florida Research Center

Disclosure: Nothing to disclose.

Franklin Flowers, MD, Department of Dermatology, Professor Emeritus Affiliate Associate Professor of Pathology, University of Florida College of Medicine

Disclosure: Nothing to disclose.

Sharron M Mason, MD, Staff Physician, Department of Internal Medicine, University of Kansas School of Medicine

Disclosure: Nothing to disclose.

Siobahn M Hruby, MD, Internal Medicine Physician, Boys Town National Research Hospital

Disclosure: Nothing to disclose.

Stephen H Mason, MD,

Disclosure: Nothing to disclose.


  1. Hyde JN, Montgomery FH. A practical treatise on disease of the skin for the use of students and practitioners. 1909. 174-175.
  2. Schuhknecht B, Marziniak M, Wissel A, Phan NQ, Pappai D, Dangelmaier J, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011 Jul. 165(1):85-91. [View Abstract]
  3. Pereira MP, Pogatzki-Zahn E, Snels C, Vu T, Üçeyler N, Loser K, et al. There is no functional small-fiber neuropathy in prurigo nodularis despite neuroanatomical alterations. Exp Dermatol. 2017 Mar 31. [View Abstract]
  4. Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011 Nov. 165(5):990-6. [View Abstract]
  5. Magand F, Nacher M, Cazorla C, Cambazard F, Marie DS, Couppié P. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg. 2011 Jul. 105(7):401-4. [View Abstract]
  6. Seshadri P, Rajan SJ, George IA, George R. A sinister itch: prurigo nodularis in Hodgkin lymphoma. J Assoc Physicians India. 2009 Oct. 57:715-6. [View Abstract]
  7. Savoia F, Casadio C, Tabanelli M, Gaddoni G, Savoia F, Patrizi A, et al. Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. Int J Dermatol. 2011 Dec. 50(12):1588-9. [View Abstract]
  8. Kestner RI, Ständer S, Osada N, Ziegler D, Metze D. Acquired Reactive Perforating Dermatosis is a Variant of Prurigo Nodularis. Acta Derm Venereol. 2017 Feb 8. 97 (2):249-254. [View Abstract]
  9. Matthews SN, Cockerell CJ. Prurigo nodularis in HIV-infected individuals. Int J Dermatol. 1998 Jun. 37(6):401-9. [View Abstract]
  10. Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. Dermatol Ther (Heidelb). 2016 Sep. 6 (3):397-411. [View Abstract]
  11. Nahass GT, Penneys NS. Merkel cells and prurigo nodularis. J Am Acad Dermatol. 1994 Jul. 31(1):86-8. [View Abstract]
  12. Vaalasti A, Suomalainen H, Rechardt L. Calcitonin gene-related peptide immunoreactivity in prurigo nodularis: a comparative study with neurodermatitis circumscripta. Br J Dermatol. 1989 May. 120(5):619-23. [View Abstract]
  13. Mattila JO, Katila ML, Vornanen M. Slowly growing mycobacteria and chronic skin disorders. Clin Infect Dis. 1996 Nov. 23(5):1043-8. [View Abstract]
  14. Mattila JO, Vornanen M, Vaara J, Katila ML. Mycobacteria in prurigo nodularis: the cause or a consequence?. J Am Acad Dermatol. 1996 Feb. 34(2 Pt 1):224-8. [View Abstract]
  15. Saporito L, Florena AM, Colomba C, Pampinella D, Di Carlo P. Prurigo nodularis due to Mycobacterium tuberculosis: a case report. J Med Microbiol. 2009 Aug 6. [View Abstract]
  16. Jacob CI, Patten SF. Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus. J Am Acad Dermatol. 1999 Aug. 41(2 Pt 2):357-61. [View Abstract]
  17. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006 Feb. 117(2):411-7. [View Abstract]
  18. Roenigk RK, Dahl MV. Bullous pemphigoid and prurigo nodularis. J Am Acad Dermatol. 1986 May. 14(5 Pt 2):944-7. [View Abstract]
  19. Tamada Y, Yokochi K, Oshitani Y, et al. Pemphigoid nodularis: a case with 230 kDa hemidesmosomes antigen associated with bullous pemphigoid antigen. J Dermatol. 1995 Mar. 22(3):201-4. [View Abstract]
  20. Feuerman EJ, Sandbank M. Prurigo nodularis. Histological and electron microscopical study. Arch Dermatol. 1975 Nov. 111(11):1472-7. [View Abstract]
  21. Perez GL, Peters MS, Reda AM, Butterfield JH, Peterson EA, Leiferman KM. Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol. 1993 Jul. 129(7):861-5. [View Abstract]
  22. Sandbank M. Cutaneous nerve lesions in prurigo nodularis. Electron microscopic study of two patients. J Cutan Pathol. 1976. 3(3):125-32. [View Abstract]
  23. Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol. 2009 Nov 30. [View Abstract]
  24. Richards RN. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg. 2010 Jan-Feb. 14(1):19-23. [View Abstract]
  25. Tupker RA, Coenraads PJ, van der Meer JB. Treatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin. Acta Derm Venereol. 1992 Nov. 72(6):463. [View Abstract]
  26. Boyd K, Shea SM, Patterson JW. The role of capsaicin in dermatology. Prog Drug Res. 2014. 68:293-306. [View Abstract]
  27. Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. Br J Dermatol. 1996 Aug. 135(2):237-40. [View Abstract]
  28. Meyers LN. Use of occlusive membrane in the treatment of prurigo nodularis. Int J Dermatol. 1989 May. 28(4):275-6. [View Abstract]
  29. Nakamura M, Koo JY. Phototherapy for the treatment of prurigo nodularis: a review. Dermatol Online J. 2016 Apr 18. 22 (4):[View Abstract]
  30. Saraceno R, Nistico SP, Capriotti E, de Felice C, Rhodes LE, Chimenti S. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed. 2008 Feb. 24(1):43-5. [View Abstract]
  31. Wollenschlager I, Hermann J, Ockenfels HM. [Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses]. Hautarzt. 2009 Nov. 60(11):898-906. [View Abstract]
  32. Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol. 2011 Jul. 25(7):799-803. [View Abstract]
  33. Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 2008 Feb. 24(1):19-23. [View Abstract]
  34. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol. 1984 Mar. 120(3):338-41. [View Abstract]
  35. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996 Dec. 35(6):969-79. [View Abstract]
  36. Orlando A, Renna S, Cottone M. Prurigo nodularis of Hyde treated with low-dose thalidomide. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr. 13(2):141-5. [View Abstract]
  37. Ferrándiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology. 1997. 195(4):359-61. [View Abstract]
  38. Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol. 1995 Nov. 33(5 Pt 1):837-8. [View Abstract]
  39. Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology. 2011. 223(2):107-12. [View Abstract]
  40. Ossorio-García L, Jiménez-Gallo D, Rodríguez-Mateos ME, Arjona-Aguilera C, Linares-Barrios M. Treatment of prurigo nodularis with lenalidomide. Dermatol Ther. 2017 Mar. 30 (2):[View Abstract]
  41. Bieber AK, Cohen DE, Stein JA. Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin. JAAD Case Rep. 2016 May. 2 (3):269-71. [View Abstract]
  42. Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014 Jun. 39 (4):468-73. [View Abstract]
  43. Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther. 2010 Mar-Apr. 23(2):194-8. [View Abstract]
  44. Dereli T, Karaca N, Inanir I, Ozturk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol. 2008 Jan-Feb. 18(1):85-6. [View Abstract]
  45. Grillo M, Long R, Long D. Habit reversal training for the itch-scratch cycle associated with pruritic skin conditions. Dermatol Nurs. 2007 Jun. 19(3):243-8. [View Abstract]
  46. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010 Jun 4. 5(6):e10968. [View Abstract]
  47. Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S. Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review. Acta Derm Venereol. 2012 Apr 16. [View Abstract]
  48. Stoll DM, Fields JP, King LE Jr. Treatment of prurigo nodularis: use of cryosurgery and intralesional steroids plus lidocaine. J Dermatol Surg Oncol. 1983 Nov. 9(11):922-4. [View Abstract]
  49. Waldinger TP, Wong RC, Taylor WB, Voorhees JJ. Cryotherapy improves prurigo nodularis. Arch Dermatol. 1984 Dec. 120(12):1598-600. [View Abstract]
  50. Lotti T, Buggiani G, Prignano F. Prurigo nodularis and lichen simplex chronicus. Dermatol Ther. 2008 Jan-Feb. 21(1):42-6. [View Abstract]

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.

Prurigo nodularis. Courtesy of Jeffrey Meffert, MD.